Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

3DVasCMD

Financiado

Development of novel 3D vascularized cardiac models to investigate Coronary Micr...

Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular Disease Coronary microvascular disease (CMD) is a significant healthcare challenge, contributing to ischemic heart disease, the number one global cause of human mortality. CMD is associated with dysfunction of small coronary vessels, due... ver más

31/03/2027

EMBL

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

EUROPEAN MOLECULAR BIOLOGY LABORATORY No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-03-14

ERC-2021-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EMBL

1.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2016-4957-1 INVESTIGACIÓN DE TERAPIAS ANGIOGÉNICAS BASADAS EN FACTOR TIS... 415K€ Cerrado

HEART2BEAT Advanced human models of the heart to understand cardiovascu... 3M€ Cerrado

3DCardiacHTS Bringing 3D cardiac tissues to high throughput for drug disc... 1M€ Cerrado

PID2019-107329RB-C21 MODELO MULTIESCALA DE LA ACTIVIDAD ELECTRICA DEL CORAZON DE... 67K€ Cerrado

IJC2018-035209-I Modelos computacionales del sistema cardiovascular 93K€ Cerrado

uBeat Mimic human complexity in a Beat to revolutionize the drug d... 75K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2022-03-14
Fecha Fin: 2027-03-31

Líder del proyecto

EUROPEAN MOLECULAR BIOLOGY LABORATORY No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 1M€

Descripción del proyecto Coronary microvascular disease (CMD) is a significant healthcare challenge, contributing to ischemic heart disease, the number one global cause of human mortality. CMD is associated with dysfunction of small coronary vessels, due to ageing, obesity and metabolic disease, that reduces blood flow and oxygenation in the heart. Despite its widespread impact on health, our understanding is limited to animal studies, which do not recapitulate the pathophysiology in humans, nor can they be used to reveal cellular crosstalk in a controlled manner. Thus, there is a critical need to develop a humanized in vitro model to mimic CMD. Advances in organ-on-chip and induced pluripotent stem cell (iPSC) technologies, together with our state-of-the-art 3D humanized vascular models, provide new opportunities to investigate CMD. 3DVasCMD builds on our expertise to develop a complex vascularized cardiac model, to reveal pathological mechanisms and novel therapeutic targets of CMD. By combining cutting-edge tissue-engineering approaches we will: 1) Develop and characterize a 3D vascularized cardiac model, 2) Determine the impact of known risk factors on the pathophysiology of CMD; 3) Develop a high-throughput system for cardiovascular drug screening. Our model will reveal cardiac tissue-vessel crosstalk by combining autologously-differentiated iPSCs in a controlled fluidic environment. This model will enable unprecedented study of ischemia, diabetes, and sex-hormone contributions to CMD using 3D in vitro tissues. Ultimately, a high-throughput version of our model, combined with machine learning, will predict the efficacy of therapeutic targets. Using an interdisciplinary approach, 3DVasCMD will impact our understanding of how microenvironmental and heritable risk-factors contribute to CMD. This model has the potential to study multiple facets of vascular disease and can be further developed into a preclinical tool, which will be a breakthrough for cardiovascular biology and medicine.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores